<DOC>
	<DOCNO>NCT00596895</DOCNO>
	<brief_summary>Primary Outcome Measures : Decrease rate serum PSA rise Secondary Outcome Measures : Adherence treatment regimens Quality life assess FACT-P baseline 12 month treatment Modulation serum testosterone , isoflavone metabolite , cholesterol Estimated Enrollment : 27 Study Start Date : November 2003 Estimated Primary Completion Date : February 2007 ( Final data collection date primary outcome measure )</brief_summary>
	<brief_title>Isoflavone Prostate-specific Antigen Recurrent Prostate Cancer</brief_title>
	<detailed_description>- Pretreatment evaluation include complete medical history , physical examination ( include digital rectal examination ) , serum PSA , free/total testosterone , lipid , serum isoflavone level ( genistein , daidzein , equol ) , assessment quality life ( Functional Assessment Cancer Treatment-Prostate , FACT-P questionnaire ) . - Whole blood obtain prior initiation study ass DNA polymorphism . - Follow-up serum PSA level assess efficacy obtain 3 , 6 , 9 , 12 month initiation treatment . - Medical history , physical examination , serum testosterone , lipid , isoflavone , quality life assess 6 12 month initiation treatment .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Raising serum PSA profile previous definitive therapy ( e.g. , radical prostatectomy external beam radiation therapy ) . Life expectancy least one year performance status &lt; 2 Zubrod scale . Metastatic locally recurrent disease demonstrate bone scan , compute tomography transrectal ultrasound , clinically symptomatic time enrollment No androgen deprivation therapy ( ADT ) chemotherapy within 12 month entry study . Known allergic reaction milk soy product exclude .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Isoflavone , PSA , prostate cancer , recurrent , quality life</keyword>
</DOC>